Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.

Abstract	This post hoc analysis of the DACO-016 phase III study evaluates the impact of decitabine on transfusion dependence and survival in 485 elderly patients with newly diagnosed acute myeloid leukemia (AML). Red blood cell (RBC) and platelet (PLT) transfusion independence, defined as no transfusions for ≥ 8 consecutive weeks, was measured in both decitabine (n = 242) and treatment choice (TC, n = 243) arms. More RBC transfusion dependent patients at baseline became transfusion independent with decitabine than with TC (26% vs. 13%; p = 0.0026). Similar results were obtained for patients who were PLT transfusion dependent at baseline (31% vs. 13%; p = 0.0069). When excluding patients who attained complete remission (CR), survival was improved in patients who achieved RBC or PLT transfusion independence, suggesting that reaching CR is not a prerequisite for deriving benefit from treatment with decitabine. In addition, patients who achieved transfusion independence with decitabine had increased treatment continuation, even in the absence of CR.
Authors	Jianming He, Liang Xiu, Peter De Porre, Ramesh Dass, Xavier Thomas
Journal	Leukemia & lymphoma (Leuk Lymphoma) Vol. 56 Issue 4 Pg. 1033-42 (Apr 2015) ISSN: 1029-2403 [Electronic] United States
PMID	25098427 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antimetabolites, Antineoplastic Decitabine Azacitidine
Topics	Acute Disease Aged Antimetabolites, Antineoplastic (therapeutic use) Azacitidine (analogs & derivatives, therapeutic use) Clinical Trials, Phase III as Topic Combined Modality Therapy Decitabine Disease-Free Survival Erythrocyte Transfusion (methods, statistics & numerical data) Humans Leukemia, Myeloid (therapy) Multivariate Analysis Outcome Assessment, Health Care (methods, statistics & numerical data) Platelet Transfusion (methods, statistics & numerical data) Randomized Controlled Trials as Topic Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!